+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Recurrent Malignant Glioma - Pipeline Insight, 2020

  • ID: 4989088
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 106 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Eli Lilly and Company
  • Istari Oncology, Inc.
  • Oblato, Inc.
  • MORE
Recurrent Malignant Glioma Overview

Recurrent Malignant Glioma Pipeline Insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the Recurrent Malignant Glioma market. A detailed picture of the Recurrent Malignant Glioma pipeline landscape is provided, which includes the disease overview and Recurrent Malignant Glioma treatment guidelines. The assessment part of the report embraces in-depth Recurrent Malignant Glioma commercial assessment and clinical assessment of the Recurrent Malignant Glioma pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Recurrent Malignant Glioma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Recurrent Malignant Glioma of pipeline development activities

The report provides insights into:
  • All of the companies that are developing therapies for the treatment of Recurrent Malignant Glioma with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Recurrent Malignant Glioma treatment.
  • Recurrent Malignant Glioma key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Recurrent Malignant Glioma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Recurrent Malignant Glioma Analytical Perspective

In-depth Recurrent Malignant Glioma Commercial Assessment Of Products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Recurrent Malignant Glioma Clinical Assessment Of Products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Recurrent Malignant Glioma report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Recurrent Malignant Glioma across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Recurrent Malignant Glioma therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Recurrent Malignant Glioma research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Recurrent Malignant Glioma .
Report Highlights
  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Recurrent Malignant Glioma .
  • In the coming years, the Recurrent Malignant Glioma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Recurrent Malignant Glioma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Recurrent Malignant Glioma treatment market. Several potential therapies for Recurrent Malignant Glioma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Recurrent Malignant Glioma market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Recurrent Malignant Glioma ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Key Questions
  • What are the current options for Recurrent Malignant Glioma treatment?
  • How many companies are developing therapies for the treatment of Recurrent Malignant Glioma?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Recurrent Malignant Glioma?
  • How many Recurrent Malignant Glioma emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Recurrent Malignant Glioma?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Recurrent Malignant Glioma market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Recurrent Malignant Glioma?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Recurrent Malignant Glioma therapies?
  • What are the clinical studies going on for Recurrent Malignant Glioma and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Recurrent Malignant Glioma?
  • How many patents are granted and pending for the emerging therapies for the treatment of Recurrent Malignant Glioma?


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Eli Lilly and Company
  • Istari Oncology, Inc.
  • Oblato, Inc.
  • MORE
1. Report Introduction

2. Recurrent Malignant Glioma
2.1. Overview
2.2. History
2.3. Recurrent Malignant Glioma Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Recurrent Malignant Glioma Diagnosis
2.6.1. Diagnostic Guidelines

3. Recurrent Malignant Glioma Current Treatment Patterns
3.1. Recurrent Malignant Glioma Treatment Guidelines

4. Recurrent Malignant Glioma - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Recurrent Malignant Glioma companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Recurrent Malignant Glioma Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Recurrent Malignant Glioma Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Recurrent Malignant Glioma Late Stage Products (Phase-III)

7. Recurrent Malignant Glioma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Recurrent Malignant Glioma Discontinued Products

13. Recurrent Malignant Glioma Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Recurrent Malignant Glioma Key Companies

15. Recurrent Malignant Glioma Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation

17. Recurrent Malignant Glioma Unmet Needs

18. Recurrent Malignant Glioma Future Perspectives

19. Recurrent Malignant Glioma Analyst Review

20. Appendix

21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Oblato, Inc.
  • Tactical Therapeutics, Inc.
  • Everfront Biotech Co., Ltd.
  • Eli Lilly and Company
  • Istari Oncology, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll